Products - Chronic liver disease | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 32 products

Date | Title

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 June 2020
Cirrhosis in over 16s: assessment and management (NG50)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
8 September 2023
Published:
6 July 2016
Elafibranor for previously treated primary biliary cholangitis (TA1016)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 November 2024
Everolimus for preventing organ rejection in liver transplantation (TA348)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Ex-situ machine perfusion devices for liver transplants: early value assessment
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
12 March 2026
Extracorporeal bioartificial liver assist therapy
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (DG48)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
7 June 2023
LiMAx system for assessing the functional capacity of the liver (MIB168)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
16 January 2019
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Liver disease (QS152)
Product type:
Quality standard
Published:
29 June 2017
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
21 February 2023
LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
Living-donor liver transplantation (IPG535)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 November 2015
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 January 2020
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
12 January 2023
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
Product type:
Guidance
Programme:
NICE guideline
Published:
6 July 2016
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Obeticholic acid for treating primary biliary cholangitis (TA443)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 April 2017
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
22 February 2022
OrganOx metra for liver transplant (MIB275)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
14 September 2021
OrganOx metra for liver transplant [ID5116]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis ID6458
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [TSID11905] [ID6529]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2015
Seladelpar for previously treated primary biliary cholangitis ID6429
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 September 2025
SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
29 August 2012
Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis (IPG631)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
14 November 2018
Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)
Product type:
Guidance
Programme:
Medical technologies guidance
Last updated:
17 January 2020
Published:
23 September 2015